Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight - PubMed (original) (raw)
. 2005 Apr;146(4):2069-76.
doi: 10.1210/en.2004-1349. Epub 2004 Dec 23.
Affiliations
- PMID: 15618356
- DOI: 10.1210/en.2004-1349
Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
Bronislava R Gedulin et al. Endocrinology. 2005 Apr.
Abstract
The effects of the incretin mimetic exenatide (exendin-4) on metabolic parameters, insulin sensitivity, and beta-cell mass were examined in nondiabetic, insulin-resistant obese fa/fa Zucker rats. After 6 wk of treatment, ad libitum-fed exenatide-treated (EX) and pair-fed vehicle control (PF) rats had comparable food intake, body weight, hemoglobin A(1c) (HbA(1c)), and fasting plasma concentrations of glucose, insulin, and lipids. Concurrent decreases in food intake and weight gain were observed in EX and PF rats, compared with ad libitum-fed vehicle control (CON) rats (P < 0.001). The increases in HbA(1c) and fasting plasma insulin concentrations that occur during the normal progression of this disease model were significantly reduced in EX and PF rats, compared with CON rats (P < 0.001). The insulin sensitivity index (ISI; glucose infusion rate to plasma insulin concentration) measured during a hyperinsulinemic euglycemic clamp was 224% higher in EX rats than CON rats (P < 0.001) and 61% higher in EX rats than PF rats (P < 0.004). The latter difference was despite comparable HbA(1c), fasting glucose, fasting insulin, total cholesterol, high-density lipoprotein, and daily food consumption between EX and PF animals. In the absence of exenatide, beta-cell mass was hyperbolically related to ISI (beta-cell mass * ISI was constant). Analogous to the disposition index, the beta-cell mass * ISI product was 63% greater in EX than PF rats (P < 0.05). Thus, exenatide increased beta-cell mass to a greater extent than would be expected in animals of comparable insulin resistance, suggesting a direct trophic effect on islet neogenesis in obese fa/fa rats independent of body weight and glycemia.
Similar articles
- Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM. Greig NH, et al. Diabetologia. 1999 Jan;42(1):45-50. doi: 10.1007/s001250051111. Diabetologia. 1999. PMID: 10027577 - Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL, Baker DE, Setter SM, Keith Campbell R. Iltz JL, et al. Clin Ther. 2006 May;28(5):652-65. doi: 10.1016/j.clinthera.2006.05.006. Clin Ther. 2006. PMID: 16861088 Review. - Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ. Holst JJ. Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.
Cited by
- Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes.
Gutgesell RM, Nogueiras R, Tschöp MH, Müller TD. Gutgesell RM, et al. Diabetes Ther. 2024 May;15(5):1069-1084. doi: 10.1007/s13300-024-01566-x. Epub 2024 Apr 4. Diabetes Ther. 2024. PMID: 38573467 Free PMC article. Review. - PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.
Liu X, Song L, Zhang Y, Li H, Cui C, Liu D. Liu X, et al. Front Pharmacol. 2023 Sep 14;14:1088670. doi: 10.3389/fphar.2023.1088670. eCollection 2023. Front Pharmacol. 2023. PMID: 37781697 Free PMC article. - Implantable device actuated by manual button clicks for noninvasive self-drug administration.
Kim CR, Cho YC, Lee SH, Han JH, Kim MJ, Ji HB, Kim SN, Min CH, Shin BH, Lee C, Cho YM, Choy YB. Kim CR, et al. Bioeng Transl Med. 2022 Apr 5;8(1):e10320. doi: 10.1002/btm2.10320. eCollection 2023 Jan. Bioeng Transl Med. 2022. PMID: 36684080 Free PMC article. - Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine - a case study of diabetes and nonalcoholic fatty liver disease.
Bao Y, Han X, Liu D, Tan Z, Deng Y. Bao Y, et al. Front Immunol. 2022 Dec 23;13:1072376. doi: 10.3389/fimmu.2022.1072376. eCollection 2022. Front Immunol. 2022. PMID: 36618372 Free PMC article. Review. - GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
Yan H, Huang C, Shen X, Li J, Zhou S, Li W. Yan H, et al. Front Endocrinol (Lausanne). 2022 Jul 13;13:923606. doi: 10.3389/fendo.2022.923606. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909522 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous